ARK Diagnostics Expands Toxicology Menu – New ARK™ Xylazine Assay
Innovative Immunoassay Offers Laboratories a Rapid, Reliable, and Sensitive Solution for Detecting Xylazine and Its Metabolites in Human Urine
Fremont, CA — ARK Diagnostics, Inc., proudly announces the launch of its ARK™ Xylazine Assay, a cutting-edge homogeneous enzyme immunoassay developed for the qualitative detection and/or semi-quantitative estimation of xylazine and its metabolites in human urine. This new addition to ARK’s growing toxicology menu is optimized for use on automated clinical chemistry analyzers, offering labs a fast, accurate, and scalable solution for detecting a growing threat in today’s drug landscape.
Xylazine is a veterinary sedative not approved for human use and has emerged as a growing public health concern in the illicit drug supply. Often mixed with fentanyl and other opioids, xylazine is increasingly linked to overdose cases across the United States. Its presence complicates overdose management, as xylazine is not an opioid and does not respond to naloxone, the standard treatment for opioid overdoses. In addition to central nervous system depression, xylazine use has been associated with severe skin ulcerations, prolonged sedation, and increased risk of fatal outcomes. As its prevalence rises, public health agencies and medical professionals are emphasizing the need for improved detection and surveillance of xylazine exposure in clinical and forensic settings.
The ARK Xylazine Assay is designed with both accuracy and ease-of-use in mind, featuring:
This product is intended for criminal justice and forensic use only in the United States.
About ARK Diagnostics
ARK Diagnostics, Inc. is a leading developer and manufacturer of high-quality in vitro diagnostic reagents for clinical laboratories worldwide. Headquartered in Fremont, California, ARK specializes in innovative homogeneous enzyme immunoassays designed for automated chemistry analyzers.
Contact Information
ARK Diagnostics, Inc.
48089 Fremont Blvd.
Fremont, California, 94538
877-869-2320
sales@ark-tdm.com
www.ark-tdm.com
To learn more about the ARK Xylazine Assay, visit www.ark-tdm.com or email sales@ark-tdm.com
Fremont, CA — ARK Diagnostics, Inc., proudly announces the launch of its ARK™ Xylazine Assay, a cutting-edge homogeneous enzyme immunoassay developed for the qualitative detection and/or semi-quantitative estimation of xylazine and its metabolites in human urine. This new addition to ARK’s growing toxicology menu is optimized for use on automated clinical chemistry analyzers, offering labs a fast, accurate, and scalable solution for detecting a growing threat in today’s drug landscape.
Xylazine is a veterinary sedative not approved for human use and has emerged as a growing public health concern in the illicit drug supply. Often mixed with fentanyl and other opioids, xylazine is increasingly linked to overdose cases across the United States. Its presence complicates overdose management, as xylazine is not an opioid and does not respond to naloxone, the standard treatment for opioid overdoses. In addition to central nervous system depression, xylazine use has been associated with severe skin ulcerations, prolonged sedation, and increased risk of fatal outcomes. As its prevalence rises, public health agencies and medical professionals are emphasizing the need for improved detection and surveillance of xylazine exposure in clinical and forensic settings.
The ARK Xylazine Assay is designed with both accuracy and ease-of-use in mind, featuring:
- Liquid-stable, ready-to-use reagents
- Semi-quantitative calibration range of 0 – 500 ng/mL
- Cutoff concentration: 10 ng/mL
- High specificity for xylazine and 4-hydroxy xylazine
- Compatibility with major automated chemistry analyzers
- Nonhazardous preservatives for safe handling
This product is intended for criminal justice and forensic use only in the United States.
ARK Diagnostics, Inc. is a leading developer and manufacturer of high-quality in vitro diagnostic reagents for clinical laboratories worldwide. Headquartered in Fremont, California, ARK specializes in innovative homogeneous enzyme immunoassays designed for automated chemistry analyzers.
Contact Information
ARK Diagnostics, Inc.
48089 Fremont Blvd.
Fremont, California, 94538
877-869-2320
sales@ark-tdm.com
www.ark-tdm.com
To learn more about the ARK Xylazine Assay, visit www.ark-tdm.com or email sales@ark-tdm.com
Category Press Releases